Abstract:Background: Venetoclax is a BH3 mimetic, which selectively inhibits Bcl-2. For older persons with newly diagnosed AML, the FDA has approved the use of venetoclax in conjunction with hypomethylating drugs or low-dose cytarabine. However, the selective inhibition of Bcl-2 in AML often results in the overexpression of Mcl-1, another dominant anti-apoptotic Bcl-2 family protein conferring venetoclax resistance. Dihydroartemisinin (DHA) is a herbal monomer that is taken orally to cure malaria. Studies have shown that DHA downregulates MCL-1 protein expression in AML cells. In the present study, we investigated whether the combination of venetoclax and DHA efficiently promotes apoptosis in AML cells. Methods: We assessed the combined effect of venetoclax and DHA on cell viability, apoptosis, combination index, and cell cycle in AML cells from AML cell lines and deno AML patients. Western blot analysis was used to validate the mechanisms of venetoclax and DHA. Results: Venetoclax efficiently impaired cell viability and dose-dependently promoted apoptosis when combined with DHA; their synergism was aptly represented by the combination index. Venetoclax and DHA had significant synergistic inhibition of cell viability both in cells from AML cell lines and in deno AML patients. The combination of venetoclax and DHA impaired cell cycle progression by arresting the cell cycle in S-phase and inducing apoptosis. Mechanistically, DHA mitigated venetoclax-induced upregulation of Mcl-1 and BCL-XL. Moreover, the combination inhibited the expression of C-MYC. Conclusions: Our findings demonstrate the synergistic, preferential antileukemic effects of venetoclax and DHA on AML cells, providing a rationale for preclinical and clinical trials by combining these agents already being used in clinical practice to treat AML.

Dihydroartemisinin Induces Apoptosis in Human Leukemia Cells Hl60 Via Downregulation of Transferrin Receptor Expression

Apoptosis of HL-60 Cells Induced by Dihydroartemisinin

Dihydroartemisinin Downregulates Vascular Endothelial Growth Factor Expression and Induces Apoptosis in Chronic Myeloid Leukemia K562 Cells

Dihydroartemisinin Down-Regulates the Expression of Transferrin Receptor in Myeloid Leukemia Cells

Dihydroartemisinin Induces Autophagy and Inhibits the Growth of Iron-Loaded Human Myeloid Leukemia K562 Cells Via ROS Toxicity.

Dihydroartemisinin Synergistically Promotes the Antileukemic Activity of Venetoclax by Downregulating Mcl-1 in Acute Myeloid Leukemia Cells

Dihydroartemisinin Induces Apoptosis of Cervical Cancer Cells Via Upregulation of RKIP and Downregulation of Bcl-2.

DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin

Dihydroartemisinin (DHA) Induces Caspase-3-dependent Apoptosis in Human Lung Adenocarcinoma ASTC-a-1 Cells

[Dihydroartemisinin Induces Autophagic Cell Death in Acute Myeloid Leukemia Cells through Oxidative Stress]

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Dihydroartemisinin induces ferroptosis in T cell acute lymphoblastic leukemia cells by downregulating SLC7A11 and activating the ATF4‐CHOP signaling pathway

[Dihydroartemisinin Inhibits the Expression of Vascular Endothelial Growth Factor in K562 Cells].

Progress on the Study of Anti-tumor Mechanisms of Dihydroartemisinin

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma Through the P38/MAPK and Wnt/β-Catenin Signaling Pathways.

Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells

B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer

Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro

[Dihydroartemisinin inhibits proliferation and induces apoptosis of rat glioma C6 cells].

Dihydroartemisinin Inhibits the Raf/ERK/MEK and PI3K/AKT Pathways in Glioma Cells.

Dihydroartemisinin inhibits HepG2.2.15 proliferation by inducing cellular senescence and autophagy